Hasil Pencarian - P Malandrakis

  • Menampilkan 1 - 7 hasil dari 7
Perbaiki Hasil
  1. 1
    S178: SAFETY AND EFFICACY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH RD IN NEWLY DIAGNOSED, TRANSPLANT INELIGIBLE MULTIPLE MYELOMA PATIENTS: A PHASE 1/2 STUDY BY THE HELLENIC SOCIETY OF HEMATOLOGY

    S178: SAFETY AND EFFICACY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH RD IN NEWLY DIAGNOSED, TRANSPLANT INELIGIBLE MULTIPLE MYELOMA PATIENTS: A PHASE 1/2 STUDY BY THE HELLENIC SOCI... oleh E. Terpos, M. Gavriatopoulou, I. Ntanasis-Stathopoulos, P. Malandrakis, D. Fotiou, N. Kanellias, S. Gkolfinopoulos, K. Manousou, E. Kastritis, M.-A. Dimopoulos

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    B08: A THIRD BNT162B2 DOSE INDUCES ANTIBODY RESPONSES AGAINST SARS-COV-2 EVEN IN PREVIOUSLY NON-RESPONDERS WITH MULTIPLE MYELOMA

    B08: A THIRD BNT162B2 DOSE INDUCES ANTIBODY RESPONSES AGAINST SARS-COV-2 EVEN IN PREVIOUSLY NON-RESPONDERS WITH MULTIPLE MYELOMA oleh E Terpos, M Gavriatopoulou, I Ntanasis-Stathopoulos, A Briasoulis, S Gumeni, P Malandrakis, E-D Papanagnou, M Migkou, N Kanellias, E Kastritis, I P Trougakos, M A Dimopoulos

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY

    P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY oleh V. Spiliopoulou, I. Ntanasis-Stathopoulos, P. Malandrakis, M. Gavriatopoulou, F. Theodorakakou, D. Fotiou, R. E. Syrigou, M. Migkou, M. Roussou, E. Eleutherakis-Papaiakovou, E. Kastritis, M. A Dimopoulos, E. Terpos

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    P57 PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA

    P57 PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA oleh I. Ntanasis-Stathopoulos, M. Gavriatopoulou, E. Eleutherakis-Papaiakovou, P. Malandrakis, V. Spiliopoulou, R.E. Syrigou, F. Theodorakakou, D. Fotiou, M. Migkou, M. Roussou, E. Kastritis, M.A. Dimopoulos, E. Terpos

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL

    P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL oleh I. Ntanasis-Stathopoulos, M. Gavriatopoulou, P. Malandrakis, D. Fotiou, N. Kanellias, M. Migkou, F. Theodorakakou, V. Spiliopoulou, R. Syrigou, E. Eleutherakis-Papaiakovou, S. Gkolfinopoulos, K. Manousou, E. Kastritis, M.A. Dimopoulos, E. Terpos

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    P16: DARATUMUMAB MONOTHERAPY HAS A FAVORABLE EFFECT ON BONE METABOLISM IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA; RESULTS OF THE PHASE 2 REBUILD STUDY

    P16: DARATUMUMAB MONOTHERAPY HAS A FAVORABLE EFFECT ON BONE METABOLISM IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA; RESULTS OF THE PHASE 2 REBUILD STUDY oleh E Terpos, I Ntanasis-Stathopoulos, E Kastritis, E Hatjiharissi, E Katodritou, E Eleutherakis-Papaiakovou, E Verrou, M Gavriatopoulou, A Leonidakis, S Delimpasi, P Malandrakis, M-C Kyrtsonis, M Papaioannou, A Symeonidis, MA Dimopoulos

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    B06 HIGH LEVELS OF CIRCULATING PLASMA CELLS AT DIAGNOSIS ARE PREDICTIVE FOR WORSE PROGNOSIS IN BOTH TRANSPLANT-ELIGIBLE AND -INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA

    B06 HIGH LEVELS OF CIRCULATING PLASMA CELLS AT DIAGNOSIS ARE PREDICTIVE FOR WORSE PROGNOSIS IN BOTH TRANSPLANT-ELIGIBLE AND -INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA oleh P. Malandrakis, I. Ntanasis-Stathopoulos, I.V. Kostopoulos, P. Roussakis, E. Eleutherakis-Papaiakovou, C. Panteli, N. Angelis, V. Spiliopoulou, N. Orologas-Stavrou, F. Theodorakakou, D. Fotiou, M. Migkou, M. Gavriatopoulou, E. Kastritis, O.E. Tsitsilonis, M.A. Dimopoulos, E. Terpos

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: